Cenexi turnaround delays
Cenexi's operational issues and capacity constraints may delay profitability, with management acknowledging a few quarters delay.
high · management_commentaryGland Pharma Limited — Q4 FY24
Gland Pharma reported a strong Q4 FY24 with consolidated revenue of INR 16,375 million (+19% YoY) and EBITDA of INR 3,587 million (+113% YoY), driven by a robust recovery in the...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Pricing pressure in US generics
While pricing has stabilized, any resurgence of price erosion could impact base business margins.
medium · analyst_questionSlow progress in biologics and China
Biologics CDMO and China market progress have been slower than anticipated, with no near-term material contribution expected.
medium · management_commentary